In other words, buyers of call and put options expiring on April 30 will suffer maximum loss if bitcoin settles at $54,000 on Friday.
“Options and futures are new critical datapoints for traders.
The month-end pullbacks happened as back then the max pain point was well below the spot price.
At press time, bitcoin is changing hands near $54,500, representing a nearly 1% gain on the day.
Image by efes from Pixabay See more from BenzingaClick here for options trades from BenzingaMega-Cap Companies On Tap For Earnings This Week Include Tesla, Apple, Alphabet, MicrosoftTesla Hits Record Production, Deliveries Despite Global Semiconductor Shortage© 2021 Benzinga.com.
A dose of the one-shot Johnson & Johnson COVID-19 vaccine is prepared at a vaccination event at Baldwin Hills Crenshaw Plaza in South Los Angeles on March 11, 2021. Mario Tama/Getty ImagesEditor’s Note: The Centers for Disease Control and Prevention and the Food and Drug Administration lifted the pause on the Johnson & Johnson COVID-19 vaccine on April 23, 2021, but the labels and fact sheets given to patients will carry a warning about the exceedingly low risk of developing blood clots.
The financial sector is comprised of companies that offer services including loans, savings, insurance, payment services, and money management for individuals and firms. Financial sector stocks include a wide range of companies involved in retail and commercial banking, accounting, insurance, asset management, credit cards, and brokerage.
DETROIT -Ford Motor Co on Tuesday took a fresh step toward taking control of electric vehicle battery design and production, saying it would establish a southeast Michigan center to research and build prototype lithium ion and solid-state cells.
to 492 billion yuan, Chan said.
The Series D funding round is structured as a $225 million investment, with another $300 million equity commitment from SoftBank available at Exscientia’s discretion.“Exscientia’s innovative use of AI to discover and design better quality drugs with greater efficiency has the potential to create important medicines faster than ever before,” SoftBank Investment Advisers’ Managing Partner Eric Chen said in the statement.The company says it has more than 20 projects in development, including two currently in clinical trials, and has partnered with firms including Bristol-Myers Squibb, Bayer AG, and Sanofi, as well as several biotech firms, Chief Financial Officer Ben Taylor said in an email.The investment is SoftBank’s latest in the U.K.
The company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raised $216 million to date from Gilead Sciences, Sequoia Capital China and Oxford Sciences Innovation among others.
Federal Reserve’s two-day meeting and the dovish monetary policy announcements from the Bank of Japan earlier today.